Northland Securities Reiterates “Buy” Rating for Motif Bio PLC (LON:MTFB)

Motif Bio PLC (LON:MTFB)‘s stock had its “buy” rating restated by analysts at Northland Securities in a research report issued to clients and investors on Thursday.

Several other equities research analysts also recently commented on the company. FinnCap reduced their price objective on Motif Bio PLC from GBX 125 ($1.62) to GBX 100 ($1.30) and set a “buy” rating for the company in a report on Wednesday, June 7th. Beaufort Securities reiterated a “speculative buy” rating and issued a GBX 110 ($1.42) price objective on shares of Motif Bio PLC in a report on Monday, June 5th.

Motif Bio PLC (MTFB) opened at 29.75 on Thursday. The stock’s market capitalization is GBX 58.28 million. The company has a 50 day moving average of GBX 31.71 and a 200-day moving average of GBX 28.24. Motif Bio PLC has a one year low of GBX 21.44 and a one year high of GBX 68.25.

TRADEMARK VIOLATION NOTICE: “Northland Securities Reiterates “Buy” Rating for Motif Bio PLC (LON:MTFB)” was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.wkrb13.com/markets/2284629/northland-securities-reiterates-buy-rating-for-motif-bio-plc-lonmtfb.html.

Motif Bio PLC Company Profile

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284629/northland-securities-reiterates-buy-rating-for-motif-bio-plc-lonmtfb.html

Receive News & Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.